JanetWilloughbyMaynardMD
Rheumatology • Baltimore, MDAssistant Professor, Medicine, Johns Hopkins University School of Medicine
Are you Dr. Maynard?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5200 Eastern Ave
Mason F. Lord Building Center Tower, Suite 4100
Baltimore, MD 21224Phone+1 410-614-3368Fax+1 410-550-2072
Summary
- Dr. Janet Maynard, MD is a rheumatologist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland. She is an Assistant Professor at Johns Hopkins University School of Medicine.
Education & Training
Johns Hopkins UniversityFellowship, Rheumatology, 2007 - 2010
Duke University HospitalResidency, Internal Medicine, 2004 - 2007
Vanderbilt University School of MedicineClass of 2004
Certifications & Licensure
MD State Medical License 2010 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Publications & Presentations
PubMed
- 37 citationsUsing four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncolo...Kathleen L. Miller, Lewis J. Fermaglich, Janet W. Maynard
Orphanet Journal of Rare Diseases. 2021-06-09 - 7 citationsImpact of Sex on Clinical Response in Rheumatoid Arthritis Patients Treated With Biologics at Approved Dosing Regimens.Lanyan Fang, Xuyang Song, Ping Ji, Yaning Wang, Janet Maynard
Journal of Clinical Pharmacology. 2020-12-03 - 9 citationsFDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.Kathleen L. Miller, Christine M. Mueller, Gumei Liu, Katherine I. Miller Needleman, Janet W. Maynard
Orphanet Journal of Rare Diseases. 2020-09-03
Press Mentions
FDA Approves New Menopause Drug to Treat Hot FlashesMay 16th, 2023- FDA Approves Veozah, First-of-Its-Kind Drug To Treat Hot FlashesMay 13th, 2023
- FDA Green Lights a New Type of Drug for Menopausal Hot FlashesMay 12th, 2023
- Join now to see all
